Building bridges between academic research and policy formulation: when costing less means costing more.

作者信息

Gafni Amiram, Birch Stephen

出版信息

Pharmacoeconomics. 2007;25(6):523-8; author reply 528-32. doi: 10.2165/00019053-200725060-00007.

DOI:10.2165/00019053-200725060-00007

PMID:17523756

Abstract

摘要

相似文献

Building bridges between academic research and policy formulation: when costing less means costing more.

Pharmacoeconomics. 2007;25(6):523-8; author reply 528-32. doi: 10.2165/00019053-200725060-00007.

Building bridges between academic research and policy formulation: the PRUFE framework - an integral part of Ontario's evidence-based HTPA process.

Pharmacoeconomics. 2006;24(11):1143-56. doi: 10.2165/00019053-200624110-00010.

Conditionally funded field evaluations: PATHs coverage with evidence development program for Ontario.

Value Health. 2010 Jun;13 Suppl 1:S8-11. doi: 10.1111/j.1524-4733.2010.00747.x.

Economic data transferability for HTA: are we there yet?

Value Health. 2009 Jun;12(4):407. doi: 10.1111/j.1524-4733.2008.00493.x. Epub 2009 Jan 12.

['Medical technology assessment'; more than just efficacy].

Ned Tijdschr Geneeskd. 2000 Mar 25;144(13):622-6.

Values and evidence colliding: health technology assessment in child health.

Expert Rev Pharmacoecon Outcomes Res. 2013 Aug;13(4):417-9. doi: 10.1586/14737167.2013.815420.

Health technology assessment in India: the potential for improved healthcare decision-making.

Natl Med J India. 2014 May-Jun;27(3):159-63.

Health economic decision-making: a comparison between UK and Spain.

Br Med Bull. 2012 Sep;103(1):5-20. doi: 10.1093/bmb/lds017. Epub 2012 Jul 24.

Revolution then evolution: the advance of health economic evaluation in Australia.

Z Evid Fortbild Qual Gesundhwes. 2014;108(7):360-6. doi: 10.1016/j.zefq.2014.08.020. Epub 2014 Sep 20.

Health technology assessment in Europe.

Scand J Public Health. 2009 Jun;37(4):335-9. doi: 10.1177/1403494809105860.

引用本文的文献

Generic and therapeutic substitutions: are they always ethical in their own terms?

Pharm World Sci. 2010 Dec;32(6):691-5. doi: 10.1007/s11096-010-9429-2.

本文引用的文献

Building bridges between academic research and policy formulation: the PRUFE framework - an integral part of Ontario's evidence-based HTPA process.

Pharmacoeconomics. 2006;24(11):1143-56. doi: 10.2165/00019053-200624110-00010.

The biggest bang for the buck or bigger bucks for the bang: the fallacy of the cost-effectiveness threshold.

J Health Serv Res Policy. 2006 Jan;11(1):46-51. doi: 10.1258/135581906775094235.

Incremental cost-effectiveness ratios (ICERs): the silence of the lambda.

Soc Sci Med. 2006 May;62(9):2091-100. doi: 10.1016/j.socscimed.2005.10.023. Epub 2005 Dec 1.

Economic evaluation of sirolimus-eluting stents.

CMAJ. 2005 Feb 1;172(3):345-51. doi: 10.1503/cmaj.1041062.

Inclusion of drugs in provincial drug benefit programs: Should "reasonable decisions" lead to uncontrolled growth in expenditures?

CMAJ. 2003 Apr 1;168(7):849-51.

NICE methodological guidelines and decision making in the National Health Service in England and Wales.

Pharmacoeconomics. 2003;21(3):149-57. doi: 10.2165/00019053-200321030-00001.

Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones?

CMAJ. 2002 Jan 8;166(1):44-7.

Changing the problem to fit the solution: Johannesson and Weinstein's (mis) application of economics to real world problems.

J Health Econ. 1993 Dec;12(4):469-76. doi: 10.1016/0167-6296(93)90006-z.

Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be?

J Health Econ. 1992 Oct;11(3):279-96. doi: 10.1016/0167-6296(92)90004-k.

Cost-effectiveness analysis: are the outputs worth the inputs?

ACP J Club. 1996 Jan-Feb;124(1):A12-4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验